Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Dec 12, 2023 (filed on Dec 14, 2023)Insider Name:Duggan Robert WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:17,999Price:$9.15
-
Dec 11, 2023 (filed on Dec 13, 2023)Insider Name:Duggan Robert WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:90,118Price:$9.36
-
Dec 08, 2023 (filed on Dec 12, 2023)Insider Name:Duggan Robert WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:116,656Price:$9.54
-
Dec 07, 2023 (filed on Dec 11, 2023)Insider Name:Duggan Robert WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:74,852Price:$9.19
-
Dec 06, 2023 (filed on Dec 08, 2023)Insider Name:Duggan Robert WOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-9,933Price:--
-
Dec 06, 2023 (filed on Dec 08, 2023)Insider Name:Duggan Robert WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:82,813Price:$9.06
-
Dec 06, 2023 (filed on Dec 08, 2023)Insider Name:Duggan Robert WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:9,933Price:$5.95
-
Dec 05, 2023 (filed on Dec 07, 2023)Insider Name:Duggan Robert WOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:66,021Price:$9.34
-
Dec 04, 2023 (filed on Dec 06, 2023)Insider Name:Duggan Robert WOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-20,347Price:--
-
Dec 04, 2023 (filed on Dec 06, 2023)Insider Name:Duggan Robert WOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-20,000Price:--
Filings by filing date
-
Dec 12, 2023 (filed on Dec 14, 2023)Insider Name:Duggan Robert WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:17,999Price:$9.15
-
Dec 11, 2023 (filed on Dec 13, 2023)Insider Name:Duggan Robert WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:90,118Price:$9.36
-
Dec 08, 2023 (filed on Dec 12, 2023)Insider Name:Duggan Robert WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:116,656Price:$9.54
-
Dec 07, 2023 (filed on Dec 11, 2023)Insider Name:Duggan Robert WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:74,852Price:$9.19
-
Dec 06, 2023 (filed on Dec 08, 2023)Insider Name:Duggan Robert WOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-9,933Price:--
-
Dec 06, 2023 (filed on Dec 08, 2023)Insider Name:Duggan Robert WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:82,813Price:$9.06
-
Dec 06, 2023 (filed on Dec 08, 2023)Insider Name:Duggan Robert WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:9,933Price:$5.95
-
Dec 05, 2023 (filed on Dec 07, 2023)Insider Name:Duggan Robert WOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:66,021Price:$9.34
-
Dec 04, 2023 (filed on Dec 06, 2023)Insider Name:Duggan Robert WOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-20,347Price:--
-
Dec 04, 2023 (filed on Dec 06, 2023)Insider Name:Duggan Robert WOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-20,000Price:--
News
Biz Brief
Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 3957 Point Eden Way HAYWARD CA 94545-3720 |
Tel: | N/A |
Website: | https://www.pulsebiosciences.com |
IR: | See website |
Key People | ||
Robert William Duggan Executive Chairman of the Board | Kevin Danahy President, Chief Executive Officer | Darrin R. Uecker Chief Technology Officer, Director |
Niv Ad Chief Science Officer - Cardiac Surgery | Gansevoort Dunnington Chief Medical Officer |
Business Overview |
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company's proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company's Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat. |
Financial Overview |
For the fiscal year ended 31 December 2023, Pulse Biosciences Inc revenues decreased from $700K to $0K. Net loss decreased 28% to $42.2M. Revenues reflect Systems segment decrease from $560K to $0K, Cycle units segment decrease from $140K to $0K, North America segment decrease from $517K to $0K, Rest of World segment decrease from $183K to $0K. Lower net loss reflects Stock-based Compensation in decrease from $733K (expense) to $0K. |
Employees: | 56 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $362.09M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$42.27M as of Dec 31, 2023 |
Net annual income (TTM): | -$42.21M as of Dec 31, 2023 |
Free cash flow (TTM): | -$33.16M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 55,225,333 as of Mar 20, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |